February 23, 2018 10:20 AM EST
R&D

Mer­ck­'s melanoma drug shows ear­ly promise for re­sis­tant can­cers in PhI tri­al

Brittany Meiling

Ear­ly news on a Mer­ck drug can­di­date has re­searchers hope­ful that the in­ves­ti­ga­tion­al ther­a­py could be used to fight drug re­sis­tant can­cers. The da­ta is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times